Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+16.05%
-12.55%
-15.72%
-2.98%
SYRE
Spyre Therapeutics Inc.
$19.14
Login to see Spyre Therapeutics Inc. (SYRE) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Chart
$14.82 (+29.15%)
$17.14 (+11.67%)
$17.14 (+11.67%)
$17.14 (+11.67%)
SYRE has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
SYRE overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
SYRE Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
SYRE Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displaySYRE Earnings
The TTM reflects 12-month period, providing review of SYRE financial performance.
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
What is SYRE current stock price?
What are SYRE stock strengths?
What risks are associated with SYRE stock?
When is SYRE next earnings report?
What is SYRE market cap and volume?
What is SYRE's current Stock IQ?
Should I buy SYRE stock right now?
Is SYRE a Strong Buy right now?
What does a 'Strong Buy' rating mean for SYRE?
What does a 'Strong Sell' rating mean for SYRE?
What factors influence SYRE's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+16.05%
-12.55%
-15.72%
-2.98%
SYRE
Spyre Therapeutics Inc.
Current Price
$19.14
Stock Insights
Strengths
Earnings are forecast to grow
Login to unlock Spyre Therapeutics Inc. (SYRE) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$14.82 (+29.15%)
$17.14 (+11.67%)
$17.14 (+11.67%)
$17.14 (+11.67%)
SYRE Analysts Opinion
SYRE Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
SYRE Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
SYRE Street view is extremely bullish and have positive views on the near-term outlook
SYRE has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
Average key support and resistance price levels.
Login to displaySYRE Earnings
The TTM data reflects the most recent 12-month period, providing overview of SYRE financial performance.
SYRE Financial Health
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
SYRE Latest Analysis
Spyre Therapeutics Announces Grants of Inducement Awards. WALTHAM Mass. Oct. 03 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics Inc. (NASDAQ:) (the Company or Spyre) a clinical-stage biotechnology company utilizing best-in-class antibody engineering dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases today announced that Spyre'.s independent Compensation Committee of the Board of Directors
Fri Oct 3, 2025
Spyre Therapeutics stock rises after Deutsche Bank initiates coverage sets $43 PT.
Fri Sep 26, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
SYRE Stock trends
SYRE Stock performance
SYRE Stock analysis
SYRE investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings
Leaders